We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.625 | -4.46% | 13.375 | 289,878 | 14:00:04 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 13.25 | 13.50 | 13.75 | 13.375 | 13.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 30.7M | -28.7M | -0.0696 | -1.92 | 57.75M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:06:51 | O | 377 | 13.483 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/6/2025 | 07:00 | UK RNS | Creo Medical Group PLC U.S. FDA clearance for SpydrBlade™ Flex |
| 02/6/2025 | 07:00 | UK RNS | Creo Medical Group PLC Director/PDMR Shareholding |
| 30/5/2025 | 07:00 | UK RNS | Creo Medical Group PLC Posting of AR&R and Notice of AGM |
| 28/5/2025 | 12:21 | ALNC |  Creo Medical hails US reimbursement milestone for Speedboat procedure |
| 28/5/2025 | 07:00 | UK RNS | Creo Medical Group PLC US Reimbursement milestone for Speedboat procedure |
| 27/5/2025 | 12:48 | UK RNS | Creo Medical Group PLC Holding(s) in Company |
| 23/5/2025 | 16:25 | UK RNS | Creo Medical Group PLC Holding(s) in Company |
| 22/5/2025 | 07:00 | UK RNS | Creo Medical Group PLC Directorate changes |
| 19/5/2025 | 11:10 | ALNC | Creo Medical has "positive outlook", despite widened 2024 loss |
| 19/5/2025 | 07:16 | ALNC | *Creo Medical expects Core Technology revenue growth between 40-60% in 2025 |
Creo Medical (CREO) Share Charts1 Year Creo Medical Chart |
|
1 Month Creo Medical Chart |
Intraday Creo Medical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/6/2025 | 19:12 | Creo Medical Group PLC 2023 | 1,179 |
| 08/6/2023 | 16:55 | Creo Medical Group... 2017 | 623 |
| 03/12/2018 | 12:41 | First use of Speedboat in mainland Europe | - |
| 09/12/2016 | 14:52 | China Real Estate Opportunities | 3 |
| 27/6/2012 | 12:52 | having a look...... | 1,095 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-06-17 15:06:53 | 13.48 | 377 | 50.83 | O |
| 2025-06-17 14:51:53 | 13.38 | 35,700 | 4,776.66 | O |
| 2025-06-17 13:55:01 | 13.40 | 74,624 | 9,995.88 | O |
| 2025-06-17 13:33:22 | 13.27 | 50,000 | 6,632.50 | O |
| 2025-06-17 13:17:25 | 13.27 | 2,923 | 387.74 | O |
| Top Posts |
|---|
Posted at 17/6/2025 09:20 by Creo Medical Daily Update Creo Medical Group Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker CREO. The last closing price for Creo Medical was 14p.Creo Medical currently has 412,473,319 shares in issue. The market capitalisation of Creo Medical is £55,147,683. Creo Medical has a price to earnings ratio (PE ratio) of -1.92. This morning CREO shares opened at 13.75p |
Posted at 28/5/2025 09:23 by someuwin Edison released a new note yesterdayCreo Medical Rightsized and refocused Creo Medical’s FY24 results unveiled a streamlined business model focused on its core advanced energy platform, following the divestment of a 51% stake in its consumables arm, Creo Medical Europe (CME; discontinued operations in the FY24 accounts). The c 74% y-o-y growth in core revenues (to £4m) was encouraging, with management guiding for a 40–60% uptick in FY25, supported by recent product launches and a growing user base. Cost optimisation efforts in H224 should deliver opex savings in the medium term (£5m anticipated in FY25), driving margin improvement. Management expects EBITDA break even by FY28, a timeline we view as undemanding, contingent on consistent execution and user base scaling. With current cash at hand (£26.5m), we estimate Creo to be funded to this milestone, with incremental optionality from the retained 49% stake in CME. We value Creo at £419m or 102p/share (£407m or 99p/share previously). See Edison site for full note |
Posted at 20/5/2025 08:55 by peterrr3 Thanks Dr B. Looks like the share price has found a floor so hopefully a steady rise. Did they mention time frames on the trial results? Some are now showing 2026, but others still this year. |
Posted at 17/2/2025 15:23 by dr biotech And finally this. I'd say I'd rather they were missing on the lower margin consumables and over performing on the core products. However overall sales are somewhat underwhelming particularly compared to their forecasts of 2-3 years ago. I continue to hold (full disclosure I reduced my holding last year). For me the real key will be in the Intuitive partnership, should the trials be positive and Intuitive decide to promote it to their many clients then it may really start to build.- Shares in Creo Medical Group PLC on Monday fell after it said full-year revenue would be below market expectations. The Chepstow, Wales-based medical device company expects to report sales of GBP30.4 million in the year to December 31, down 1.3% from GBP30.8 million a year prior. Chris Donnellan, director of research at Cavendish Securities noted this was below his GBP31.3 million forecast. Creo reported a 74% increase in Creo Core Technology revenue to GBP4.0 million from GBP2.3 million, with GBP2.4 million of sales in the second half, representing 50% growth half-on-half. Donnellan said this was ahead of his GBP3.4 million projection. Creo Core Technology revenues include sales from all core products such as Speedboat UltraSlim and Croma platform and significant new customer additions during the period. The sales shortfall arose in Creo Medical Europe Consumables revenue, Donnellan explained, where revenue is expected to drop to GBP26.4 million from GBP26.8 million, reflecting some forex headwinds in the period. Donnellan had expected revenue to pick up to GBP27.9 million. In response, shares in Creo Medical were 7.4% lower at 17.50 pence each in London early Monday afternoon. Creo said actions to reduce costs in the second half of the year resulted in a decrease in operating costs of around GBP5.0 million with the full benefit to come through in financial 2025. The start to the year has been positive and the company is trading in line with management expectations, it added. Donnellan said he remains "positive on the shares and confident in Creo's technology and the benefits it can deliver to patients, care providers and investors." B |
Posted at 17/2/2025 11:57 by dr biotech Worthwhile post from another board. I can't verify the accuracy, but the poster seems decent enoughPlease find the following research summary for Creo Medical, from Cavendish and Deutsche Numis, following the Company’s trading update issued this morning. Cavendish reiterates 70p target price: “Creo Medical has provided trading update for FY24, noting core Creo revenues grew 74% to £4.0m (FY23: £2.3m) versus our forecast £3.4m. Creo has reduced its operating costs through 2024, resulting in a decrease of c£5.0m, with the full benefit expected in FY25. Last week, the sale of a 51% stake in Creo Europe was completed and the cash (c€30m) was received on 14 Feb 2025. Management notes that trading in 2025 is in line with its expectations. We remain positive on the shares and confident in Creo’s technology and the benefits it can deliver to patients, care providers and investors.” Deutsche Numis reiterates Buy recommendation and 45p target price: “The surgical endoscopy and advanced energy company expects sales of £30.4m for FY24 (DBe £31.6m). Core technology sales of £4m are in line with expectations growing 76%, benefiting from significant new customer additions in the year. H2 sales of £2.4m grew 50% over H1. The Consumables business grew 3% on CER (DBe 3%), but due to FX headwinds delivered sales of £26.4m, a touch light of expectations (DBe £27.6m). The disposal of 51% of the Consumables business has completed and the cash was received last week. FY25 has started positively and a fuller update will be provided at FY24 results in April.” |
Posted at 15/1/2025 07:03 by bloomberg2 Creo Medical Group plc("Creo" the "Company" or the "Group") First robotic-guided lung ablation cases commenceas part of Intuitive collaboration agreement Robotic-guided microwave ablation of cancerous lung tissue now being undertaken at two UK sites Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the first robotic-guided microwave ablation of cancerous lung tissue cases have commenced at a leading UK hospital (the "Hospital"). As announced in July 2024, the Company amended its multi-year collaboration with Intuitive and this latest robotic-guided microwave ablation procedure for lung cancer is the first clinical case using Intuitive's Ion Endoluminal System and Creo's MicroBlate Flex ablation device to take place under the amended terms of the agreement at the Hospital. The Hospital is now the second site to have performed microwave ablation procedures for lung cancer. The first UK site to perform such procedures was the Royal Brompton Hospital as part of an ongoing clinical study1 conducted by Professor Shah. The Pioneer Programme will continue to roll-out throughout 2025 to support the collection of clinical evidence ahead of the sites entering a commercial phase, and the Company expects the number of procedures performed to grow in the current year. Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted that this first clinical site under the Pioneer Programme, representing a second UK clinical site, has started clinical practice and successfully completed their first robotic-guided lung cancer ablation procedure using Creo's MicroBlate Flex alongside Intuitive's Ion Endoluminal System. With both the clinical study at the Royal Brompton and this site as part of the clinical Pioneer Programme, we now have two UK hospitals undertaking these procedures. These sites, under the amended collaboration agreement with Intuitive, will provide us with the clinical evidence needed to support the wider commercialisation of the MicroBlate Flex device. We look forward to updating shareholders on our progress." |
Posted at 12/11/2024 12:14 by purchaseatthetop The problem is that it is going nowhereTotal revenue of £15.2m (H1-2023: £15.7m) Gross margin stuck at 47% Losses of £10m each six months. The hope of the 51% strategic sale looks very uncertain We announced on 18 September 2024 that Creo has entered into a binding agreement with Micro-Tech (NL) International B.V., a wholly owned subsidiary of Micro-Tech (Nanjing) ("Micro-Tech") for the sale of 51% of the issued share capital of Creo Medical S.L.U. ("Creo Medical Europe"), a wholly owned subsidiary of Creo, at an equity value of €72m (the "Sale") on a cash-free, debt-free basis. The net proceeds payable to Creo from the Sale (the "Proceeds") will strengthen the Group's balance sheet, enabling us to continue to invest in our core Creo and Kamaptive business and deliver on our commercial and operational objectives. The Proceeds are expected to be approximately €30m, which will be payable in cash on completion. Ongoing shareholder terms have also been agreed which include a future exit framework for Creo. Along with other customary conditions, completion of the Sale is contingent on Micro-Tech obtaining Outbound Direct Investment clearance in China along with Foreign Direct Investment clearances in Spain, France, Belgium and Germany. Whilst there is no certainty as to receipt or timing of receipt of the necessary approvals to enable completion, it is expected that completion will take place during Q1 2025 dependent on these relevant clearances being obtained. Too many future uncertains. |
Posted at 12/11/2024 10:01 by parob Few more for me on that drop. The share price down here is very close to the all time low which we hit on Friday of last week at around 16.25p so there really are not that many in profit around this level. There may be a few that sell for 10/15% I suppose and perhaps thats what we saw earlier. I am hopeful the recovery will speed up once these initial profit takers are out. At 18p to buy the share price is 25% cheaper than the recent £12M placing price of 24p where the directors put about £750k in. |
Posted at 06/11/2024 09:47 by 1swifty Frustrating times with Creo. No news, share price dropping, lots of sells. Crazy fall since the impressive and positive news of stake sold in Creo Europe. If sale goes through cash available could be significant percentage of current market capital thus making current share price crazy low. |
Posted at 19/10/2024 10:41 by networker I am not aware if CREO made any comments at yesterday's EGM held in Bristol.Here are their recent (official) comments on recent events:- "As you know the Company announced its strategic partnership with Micro-Tech and the intended disposal of a 51% stake in Creo Europe. Unfortunately, Creo Medical wasn’t in a position to arrange the Placing to coincide with the disposal. After the Micro-Tech news was released a broker’s research note was published that restated again the analyst’s view that the Company had a funding requirement, and that they continued to assume that Creo Medical would need additional cash to bridge through to proceeds from the disposal (although less than previously expected given the transaction). Given the current environment of the equity markets this led to a drag on the share price. In addition, since the announcement of the fundraising, there has been an institutional seller in the market (for non-Creo specific reasons), which has caused further downward pressure. At the same time as there has been a lack of buying activity across equity markets generally due to concerns about what might be announced in the upcoming budget. The Company and its advisers are working hard to ensure that this overhang is cleared and that the share price recovers. " |
Posted at 17/10/2024 17:36 by bloomberg2 17 October 2024Creo Medical Group plc("Creo" or the "Company") Result of Retail Offer Further to the announcements dated 30 September 2024 and 4 October 2024 in relation to the Retail Offer, Creo announces that, following the closing of the Retail Offer by BookBuild earlier today, 369,109 Retail Offer Shares will be issued at an Issue Price of 24 pence per Retail Offer Share in connection with the Retail Offer. Consequently, a total of 50,369,109 New Ordinary Shares, comprising 50,000,000 Placing Shares and 369,109 Retail Offer Shares will be issued conditional on the passing of the Resolutions by Shareholders at the General Meeting to be held on 18 October 2024. Admission, settlement and dealings Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to take place at 8:00 a.m. on 21 October 2024 and dealings in the New Ordinary Shares are expected to commence at 8.00 a.m. on 21 October 2024 or such later time and/or date as the Joint Bookrunners and the Company agree (being in any event no later than 8.00 a.m. on 11 November 2024). The New Ordinary Shares, when issued, will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Capitalised terms used but not defined in this announcement have the same meanings as set out in the circular to Shareholders dated 1 October 2024. For further information please contact: Creo Medic |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
